Publication for NFKB2 and NFKBIA

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	NFKB2	nuclear factor kappa B subunit 2	4791			[link]
hsa	NFKBIA	NFKB inhibitor alpha	4792

Pubmed ID	Priority	Text
31134075	0.97	Nfkbia-/- and Nfkb2-/- MEFs upon TNFp treatment (top panel).
	0.92	Nfkb2-/- MEFs a low level of basal RelB:p50 activity; targeting IkappaBalpha-bound complexes, TNFp further augmented this RelB activity at 0.5 h post-stimulation that was diminished to the basal level by 1 h (Figure S2B).
	0.73	IkappaBalpha, strengthens this constitute RelB:p50 activity present in Nfkb2-/- MEFs.
	0.50	Nfkbia-/- and Nfkb2-/- MEFs, was determined in the shift-ablation assay.
27641334	0.97	IkappaBalpha complex was augmented in Nfkb2-/- MEFs (Figure 3b).
	0.64	IkappaBalpha in WT and in Nfkb2-/- cell systems.
20051107	0.97	IkappaBalpha phosphorylation and subsequent proteasomal degradation, the alternative pathway depends on IKKalpha homodimers and NF-kappaB-inducing kinase (NIK) and results in regulated processing of the p100 precursor protein to p52 via phosphorylation and degradation of its IkappaB-terminus.
29079592	0.96	IkBalpha and p42/44 and upregulation of p52 expression after rhCXCL12 treatment, as shown by western blot analysis for HBL-2 (Figure 4B).
	0.90	IkappaBalpha, phospho-IkappaKalpha and p52) could be detected (B and C), shown by western blot analysis and immunoprecipitation (IP).
	0.82	IkappaBalpha and IKKalpha accompanied by a decrease in p52 could be observed.
	0.79	IkBalpha and p52, as shown by western blot analysis (B).
	0.64	IkBalpha led to the phosphorylation of IkBalpha and to an increase in p52 in MCL cell lines (Figure 3C).
21375523	0.96	IkappaBalpha (serine 32/36), and processing of p100 to p52 (B).
	0.83	IkappaBalpha, diminished belinostat-mediated RelA/p65 hyperacetylation (K310), and reduced processing of p100 into p52.
21113390	0.96	IkappaBalpha and the abundance of nuclear p52.
27821799	0.95	p52 processing, and reduced IkappaBalpha levels (Figure 7B), indicating activation of both NF-kappaB signaling pathways.
22388891	0.94	NFKB2, MCP-1, VCAM-1 and NFKBIA (Fig. 4a).
19765279	0.90	NFKBIA, NFKBIE, APAF1, NFKB2, NFKB1, BIRC3), role of PKR in interferon induction and antiviral response (CASP9, NFKBIA, NFKBIE, APAF1, NFKB2, NFKB1) and RAR activation (SRC, PRMT2, RDH11, ADCY3, PRKACA, NFKB2, NFKB1, MAPKAPK2, RBP1, MMP1, PTEN).
21170083	0.90	IkappaBalpha, p100, after phosphorylation at Ser 866 and Ser 870, undergoes limited processing to generate p52, also regulated by SUMOylation.
11748286	0.86	p52/100, p65/RelA, RelB, or c-Rel), and is regulated by members of the IkappaB family of inhibitors, principally IkappaBalpha, which binds to NF-kappaB dimers and retains them in the cytoplasm.
27043634	0.86	p52 NF-kappaB complex using a mechanism that relies on the inducible processing of p100 instead of degradation of IkappaBalpha (Figure 1).
24287697	0.82	p52, RelB and IkappaBalpha were analyzed by western blotting.
27197231	0.79	p52, elevated the level of NIK and IkappaBalpha (Fig. 4A), decreased nuclear p65 level whereas elevated nuclear p52 level(Fig.
	0.58	IkappaBalpha, and the activation of the non-canonical pathway relies on stabilization of NIK and processing of NF-kappaB2 p100 precursor to p52.
26988706	0.78	NFKBIA gene with overlapping peaks for p50, p52, RelA, and RelB in the promoter and first intron.
	0.72	p52 and RelB (for example, NFKBIA gene).
25681335	0.76	IkappaBalpha-dependent canonical pathway, the IL-10 expression is IkappaBalpha-independent, and its inhibition is associated with the increased promoter recruitment of p52 that characterizes the non-canonical pathway.
	0.73	IkappaBalpha-dependent and is regulated by the canonical pathway, the IL-10 expression is IkappaBalpha-independent, and its inhibition by BZ is associated with increased promoter recruitment of p52 that characterizes the non-canonical pathway.
	0.69	IkappaBalpha-independent, and activates complexes containing mostly RelB and p52.
19524538	0.76	p52 proteins interact with p105 and p100, we fractionated the cytoplasmic extract of THP-1 cells by gel filtration chromatography in the presence and absence of DOC and analyzed the resulting fractions by western blotting with antibodies specific for p52/p100 (Figure 4D, top), p50/p105 (Figure 4D, middle), and IkappaBalpha (Figure 4D, bottom).
	0.58	ikba-/-ikb-/-ikbbe-/-, wild-type (WT), and nfkb1-/-nfkb2-/- MEF were analyzed by GF in the presence of 0.5% DOC.
24634471	0.75	IkappaBalpha, decreased nuclear translocation of p65 and p52 leading to inhibition of both canonical and non-canonical NFkappaB pathways, and reduced transcription of their target genes, notably chemokines.
31731625	0.75	NFKB2, (E,F) RELA, (G,H) NFKBIA, (I,J) NFKBIB, (K,L) IKBKG, (M,N) NFKBIE.
25129674	0.74	NFKB2, NFKBIA, NFKBIE and IKBKE), all with increased expression, are collectively found in 28 of these pathways, including the NF-kappaB pathway itself.
21203422	0.73	IkappaBalpha, IkappaBbeta and IkappaBepsilon, which are present in the cytoplasm of unstimulated cells and undergo stimulus-induced degradation; (b) precursor proteins, p100 and p105, which can be processed to form the NF-kappaB family members p52 and p50, respectively; and (c) atypical/nuclear IkappaB proteins, namely IkappaBzeta, Bcl-3 and IkappaBNS, which are not generally expressed in unstimulated cells but are induced upon activation to mediate their effects in the nucleus.
23259744	0.72	IkappaB-alpha and, in the case of M10 cells, also drug-induced enhancement of NF-kappaB2/p52 levels.
	0.70	IkappaB-alpha degradation and NF-kappaB2/p52 generation.
19258426	0.71	IkappaB-alpha phosphorylation and translocation of p65/50 to the nucleus, but not the processing of p52 from p100, suggesting inhibition of NF-kappaB regulator IKKbeta rather than IKKalpha.
20466000	0.71	IkappaBalpha, LPS induced translocation of RelB and p52 into the nucleus, in order to influence the transcription of inflammatory genes, such as IL-8, and innate immune responses.
26506125	0.68	IkBalpha and involves p100 phosphorylation and processing to the NFkB active subunit p52.
24533079	0.66	p52 DNA binding and stronger IkappaBalpha phosphorylation compared with RMG-I cells, suggesting predominant canonical NF-kappaB activation in JHOC-5 cells.
28689659	0.66	p52 homodimers from active promoters just like the removal of p50:RelA heterodimer by IkappaBalpha.
27187478	0.64	IkappaBalpha degradation, the non-canonical NF-kappaB pathway relies on the inducible processing of p100 and is characterised by nuclear translocation of the RelB/p52 heterodimer.
19746155	0.63	p52/p100, RelB and cRel), which share a common Rel homology domain, typically exists as homo- or hetero-dimers in the cytoplasm where they are bound by inhibitory kappaB proteins (IkappaB), such as IkappaBalpha.
23028875	0.62	p52 and p105/p50) defined by the presence of the Rel homology domain, which enables DNA binding and interaction with IkappaB. Canonical NF-kappaB activation utilises an IKKbeta-containing complex to drive phosphorylation and degradation of the classical IkappaB proteins IkappaBalpha, IkappaBbeta and IkappaBepsilon resulting in predominantly release of the p65/p50 dimer.